medigraphic.com
ISSN 2305-7939 (Electronic)

2019, Number 1

<< Back Next >>

RCU 2019; 8 (1)

Relationship of prostatitis in the appearance of prostate cancer and benign prostatic hyperplasia

Repetto E, Sosa A, Colla R, Revol M, Metrebian E, Metrebian S

Language: Spanish
References: 19
Page: 22-33
PDF size: 827.88 Kb.


ABSTRACT

Introduction: Prostate cancer is the most common type of cancer in adult men. Benign prostatic hyperplasia (BPH) is the most frequent benign pathology, not forgetting the high incidence of prostatis. Objective: To demonstrate if there is an association between prostatic infections and the risk of suffering other pathologies of this organ (Benign prostatic hyperplasia and prostate cancer). Methods: Our study was divided into 3 groups, patients who underwent a prostate biopsy (n: 420), patients who underwent radical prostatectomy (n: 121), patients who underwent surgery for Benign prostatic hyperplasia (n: 218). Results: Group 1, of the 420 patients who underwent biopsy, 78 had prostate cancer, patients with prostate cancer and prostatitis represent 61.53 %. Group 2, a significant relationship was found in patients with prostate cancer and prostatitis with in the low risk group. Group 3 of patients with prostatitis, 54.27 % had prostates greater than 100 grams and this is statistically significant. Conclusions: With the present study we could verify the hypothesis that there is an association between prostatic infections and the risk of suffering other pathologies of this organ (Benign prostatic hyperplasia and prostate cancer). In the case of prostate cancer, it tends to favor low-grade pathology (Gleason 6), which could be candidates for active surveillance at an early stage of their disease, then we have to think about the importance of early diagnosis and treatment of the prostatitis.


REFERENCES

  1. Rohena-Rivera K, Sánchez-Vázquez MM. IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer. PLoSOne. 2017 [citado Dic 2017];12:4.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/283799 5

  2. Taoka R, Kakehi Y. The influence of asymptomatic Inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol. 2017 [citado Oct 2017];4:158-63. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5717984/

  3. Yang KQ, Liu Y, Huang QH. Bone marrowderived mesenchymal stem cells induced by inflammatory cytokines produce angio genetic factors and promote prostate cancer growth. BMC Cancer. 2017 [citado Jun 2017];17:878-81. Disponible en: https://bmccancer.biomedcentral.com/articles

  4. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013 [citado Oct 2017];1:5-10. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/231599 91

  5. Krušlin B, Tomas D, Džombeta T. Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach. Front Oncol. 2017 [citado Dic 2017];25:77-82. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5403898/

  6. Tuppin P, Samson S, Fagot-Campagna A. PSA testing, biopsy and cancer and benign prostate hyperplasia in France.Prog Urol. 2014 [citado Dic 2017];24:572-80. Disponible en: https://www.urologiesante. fr/fileadmin/documents/data/.../2014/... /main

  7. Haverkamp J, Charbonneau B, Prostate In?ammation and Its Potential Impact on Prostate Cancer: A Current Review. Journal of Cellular Biochemistry. 2008 [citado Jun 2017];103:1344-53. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/179555 03

  8. Porcaro AB, Rubilotta E, Petrozziello A. Chronic inflammation of the prostate type IV with respectto risk of prostate cáncer. Arch Ital Urol Androl. 2014 [citado Dic 2017];30:208-11. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5730755/

  9. Dennis LK, Lynch CF, Epidemiologic association between prostatitis and prostate cancer. Urology. 2002 [citado Dic 2017];60:78- 83. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/121009 2

  10. Vela Navarrete R, Enguita C, Prostatitis crónica: una revisión crítica de su actual definición nosológica, clasificación y potencial carcinogénesis. Arch. Esp. Urol. 2007 [citado Dic 2017];60:617-23. Disponible en: scielo.isciii.es/pdf/urol/v60n6/original1.pdf

  11. Angelo M, De Marzo M, Inflammation, atrophy, and prostate carcinogenesis. Urologic Oncology. 2007 [citado Dic 2017];25:398-400. Disponible en: https://www.urologiconcology.org/article/S107 8-1439(07)00139-1/references

  12. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V. Prostate growth and inflammation. Journal of Steroid Biochemistry & Molecular Biology. 2008 [citado May 2017];108:254-60. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/179359 71

  13. Palapattu G, Sutcliffe S, Bastian P, Platz E. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2004 [citado Jun 2017];26:1170-81. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/154987 84

  14. Boehm K, Valdivieso R, Meskawi M. Prostatitis, other genitor urinary infections and prostate cancer: results from a populationbased case-control study. World J Urol. 2016 [citado Jun 2017];34:425-30. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5207623/

  15. Boehm K, Valdivieso R, Meskawi M, Larcher A. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS). World J Urol. 2015 [citado Dic 2017];33:2063-69. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/258245 39

  16. Sciarra A, Di Silverio F, Salciccia S, Autran- Gomez AM, Gentilucci A, Gentile V. Inflammation and Chronic Prostatic Diseases: Evidence for a Link. European Urology. 2007;52:964-72. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/176180 43

  17. Platz E, Demarzo A. Epidemiology of inflammation and prostate cancer. J Urol. 2004 [citado Dic 2017];176:36-40. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/147137 51

  18. Tuxhorn J, Ayala G, Rowley DR. Reactive stroma in prostate cancer progression. The journal of urology. 2001 [citado Nov 2017];166:2472-83. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/116968 14

  19. Puhr M, De Marzo A, Isaacs W, Lucia MS. Inflammation, Microbiota, and Prostate Cancer. Eur Urol Focus. 2016 [citado Dic 2017];4:374-82. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28723469




2020     |     www.medigraphic.com